COVID-19 Group Testing Method Delivers Results 13 Times Faster than Individual Testing of Each Sample
|
By LabMedica International staff writers Posted on 30 Mar 2021 |

Illustration
A new group method of testing for COVID-19 allows results to be obtained 13 times faster as compared to individual testing of each sample.
The new method developed by researchers from the HSE Laboratory of Algorithms and Technologies for Networks Analysis (Nizhny Novgorod, Russia) and Vilnius University (Vilnius, Lithuania) can be used for asymptomatic populations with seemingly low incidence of coronavirus cases, where it will help detect the infected individuals at a maximum speed with a minimum number of tests, and timely apply the quarantine measures in order to prevent spreading of the disease.
Present COVID-19 testing solutions are based on the extraction of RNA from patients using oropharyngeal and nasopharyngeal swabs, and then testing with real-time PCR for the presence of specific RNA filaments identifying the virus. The speed of this approach is limited by the availability of reactants, trained technicians and laboratories. One way to speed up the testing procedures is group testing, where the swabs of multiple patients are grouped together and tested. The swabs from groups that return a positive result are then tested individually in order to detect specific COVID-19 positive patients. This approach helps decrease the number of tests twofold or more (depending on the spread of the disease) as compared to individual testing of each swab.
For example, suppose 96 samples should be tested and pools of up to 12 samples are possible. In individual testing, 96 tests are necessary. In pool testing, 8 pools of 12 samples are taken and testing is performed. If the result of one pool is positive, then additional 12 individual tests are needed. If two or three groups return a positive result, 24 or 36 additional tests are required, which, together with the first eight tests, will mean a decrease in the number of tests from two to five times as compared to individual testing. The researchers believe that the number of tests can be decreased by optimizing the size of groups that takes into account the total number of swabs and the forecasted number of infected individuals. As the number of infected individuals increases, the possibility of saving swabs decreases but is still about 40% in the event of an incidence of 100 positive samples per 1,000, and 18% for an incidence of 200 per 1,000.
There are ways to optimize group testing, such as choosing the optimal group size based on the total number of swabs and the projected level of disease spreading. Another is the binary splitting method, in which a positive group is split into halves and is tested again, until individual positive swabs are detected. The second method, however, is very time-consuming, which decreases its attractiveness during a pandemic. In addition, to optimize group testing, transposition-based replication is used: after grouping the swabs, researchers form additional control groups from the same swabs and test them together with the main groups. This helps further cut the number of tests, and if the disease levels are low, it also helps to detect positive swabs in one step, which speeds up the testing considerably.
However, this method does not allow for experimenting with group sizes to detect the optimal group size under specific conditions. Researchers from HSE University and Vilnius University suggested OptReplica technology, which uses a more complicated algorithm of swab grouping in key and control groups and helps decrease the number of control groups. In addition, the algorithm helps calculate the optimal group size for the present number of swabs and the forecasted level of disease spreading. The researchers conducted experimental research on samples of 96 and 384 swabs, carrying out 100 randomized tests for each sample size, and compared the effectiveness of transposition-based replication and OptReplica method for different levels of disease incidence. The studies have shown that if the optimal size of groups is chosen, OptReplica is more effective than transposition-based replication. In cases with low incidence, the use of OptReplica, a 13x average reduction of tests can be achieved compared to individual testing without time delay.
“Our simulations are actually proving that using this optimization replication strategy is always advantageous and, even in case of high spread of the disease (10% or 20% of positives in the population), we are still competitive with individual testing strategy,” explained Mario Guarracino, Chief Research Fellow of the Laboratory of Algorithms and Technologies for Networks Analysis.
Related Links:
HSE Laboratory of Algorithms and Technologies for Networks Analysis
Vilnius University
The new method developed by researchers from the HSE Laboratory of Algorithms and Technologies for Networks Analysis (Nizhny Novgorod, Russia) and Vilnius University (Vilnius, Lithuania) can be used for asymptomatic populations with seemingly low incidence of coronavirus cases, where it will help detect the infected individuals at a maximum speed with a minimum number of tests, and timely apply the quarantine measures in order to prevent spreading of the disease.
Present COVID-19 testing solutions are based on the extraction of RNA from patients using oropharyngeal and nasopharyngeal swabs, and then testing with real-time PCR for the presence of specific RNA filaments identifying the virus. The speed of this approach is limited by the availability of reactants, trained technicians and laboratories. One way to speed up the testing procedures is group testing, where the swabs of multiple patients are grouped together and tested. The swabs from groups that return a positive result are then tested individually in order to detect specific COVID-19 positive patients. This approach helps decrease the number of tests twofold or more (depending on the spread of the disease) as compared to individual testing of each swab.
For example, suppose 96 samples should be tested and pools of up to 12 samples are possible. In individual testing, 96 tests are necessary. In pool testing, 8 pools of 12 samples are taken and testing is performed. If the result of one pool is positive, then additional 12 individual tests are needed. If two or three groups return a positive result, 24 or 36 additional tests are required, which, together with the first eight tests, will mean a decrease in the number of tests from two to five times as compared to individual testing. The researchers believe that the number of tests can be decreased by optimizing the size of groups that takes into account the total number of swabs and the forecasted number of infected individuals. As the number of infected individuals increases, the possibility of saving swabs decreases but is still about 40% in the event of an incidence of 100 positive samples per 1,000, and 18% for an incidence of 200 per 1,000.
There are ways to optimize group testing, such as choosing the optimal group size based on the total number of swabs and the projected level of disease spreading. Another is the binary splitting method, in which a positive group is split into halves and is tested again, until individual positive swabs are detected. The second method, however, is very time-consuming, which decreases its attractiveness during a pandemic. In addition, to optimize group testing, transposition-based replication is used: after grouping the swabs, researchers form additional control groups from the same swabs and test them together with the main groups. This helps further cut the number of tests, and if the disease levels are low, it also helps to detect positive swabs in one step, which speeds up the testing considerably.
However, this method does not allow for experimenting with group sizes to detect the optimal group size under specific conditions. Researchers from HSE University and Vilnius University suggested OptReplica technology, which uses a more complicated algorithm of swab grouping in key and control groups and helps decrease the number of control groups. In addition, the algorithm helps calculate the optimal group size for the present number of swabs and the forecasted level of disease spreading. The researchers conducted experimental research on samples of 96 and 384 swabs, carrying out 100 randomized tests for each sample size, and compared the effectiveness of transposition-based replication and OptReplica method for different levels of disease incidence. The studies have shown that if the optimal size of groups is chosen, OptReplica is more effective than transposition-based replication. In cases with low incidence, the use of OptReplica, a 13x average reduction of tests can be achieved compared to individual testing without time delay.
“Our simulations are actually proving that using this optimization replication strategy is always advantageous and, even in case of high spread of the disease (10% or 20% of positives in the population), we are still competitive with individual testing strategy,” explained Mario Guarracino, Chief Research Fellow of the Laboratory of Algorithms and Technologies for Networks Analysis.
Related Links:
HSE Laboratory of Algorithms and Technologies for Networks Analysis
Vilnius University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









